Respiratory Medicine News

Paxlovid did not reduce the risk for long COVID among vaccinated, nonhospitalized people who received it within a month of their first SARS-CoV-2 infection, a study showed.

COVID-19 vaccination provided strong and durable protection among children and adolescents during two strong waves of infections, according to real-world study findings reported in Annals of Internal Medicine.

In September 2021, the Biden administration introduced the American Pandemic Preparedness Plan, a proposal to transform the country’s capabilities to respond to future pandemics.

Researchers linked more than 1 million deaths in Africa in 2019 to antimicrobial resistance, more than half of which were linked to just four pathogens.

Maternal influenza vaccination during pregnancy was associated with reduced chances of influenza-associated ED visits or hospitalizations in infants aged younger than 6 months, according to a study published in JAMA Pediatrics.

Multiple prevention tools against respiratory syncytial virus in children became available in the United States this year.

SARS-CoV-2 rebound risk is more likely related to the individual person, rather than reinfection or resistance to treatment such as Paxlovid, according to two studies.

Efforts to raise flagging childhood vaccination rates increased in 2023 as new shots hit the market.

The FDA in 2023 approved treatments for several hospital-associated infections and fully approved a long-used COVID-19 medication, among other non-vaccine-related regulatory decisions.

Major vaccine developments in 2023 included the approvals of the first two vaccines against respiratory syncytial virus, the first chikungunya vaccine, a new vaccine against malaria, and a move to new monovalent COVID-19 vaccines.